ELDN

Eledon Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website eledon.com
Employees(FY) 17
ISIN US28617K1016

Performance

-20.12%

+29.63%

+39.75%

+27.48%

+113.89%

YTD

+215.57%

Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Advanced Technical Analysis

Technical Analysis of ELDN 2024-11-20

The stock indicators reflect a neutral sentiment overall, with the Moving Average Score at 50 indicating a balanced trend, while the Oscillators and Technical Scores at 43 and 46 suggest a slight bearish inclination. This combination implies that while there is no strong bullish momentum, caution is advised as the market sentiment leans towards ...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ELDN

Stock Rank

Recent News & Updates

2024-11-12 03:01
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results(Globenewswire)
2024-11-06 03:05
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference(Yahoo Finance)
2024-10-28 19:46
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants(Globenewswire)
2024-10-28 19:45
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine(Globenewswire)
2024-09-11 04:05
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference(Globenewswire)
2024-09-03 19:00
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients(Globenewswire)
2024-08-14 05:21
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results(Globenewswire)
2024-07-28 19:00
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection(Globenewswire)
2024-07-02 04:05
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism(Globenewswire)
2024-06-16 21:36
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues(Investorplace)
2024-06-11 03:18
3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024(Investorplace)
2024-06-03 04:01
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation(Globenewswire)
2024-05-26 21:55
Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now(Zacks)
2024-05-22 00:00
Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy?(Zacks)
2024-05-14 00:00
Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade(Zacks)
2024-05-09 01:54
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024(Investorplace)
2024-05-08 19:30
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results(Globenewswire)
2024-05-08 19:00
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress(Globenewswire)
2024-05-06 19:05
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection(Globenewswire)
2024-05-06 19:00
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement(Globenewswire)
2024-03-28 04:01
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results(Globenewswire)
2024-03-25 04:56
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection(Globenewswire)
2024-03-20 22:31
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human(Globenewswire)
2024-02-13 06:01
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-01-04 03:40
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook(Globenewswire)
2023-12-04 05:00
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2023-11-29 03:05
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference(Globenewswire)
2023-11-09 03:01
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results(Globenewswire)
2023-11-08 03:05
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference(Globenewswire)
2023-11-01 21:05
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.